Analytical Data
-
Gene name
TM4SF1 Protein-VLP
- Application
-
Alternative Names
M3S1; TAAL6; H-L6; L6
-
Species
Human
-
Source
HEK293
-
Tag
Tag Free
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P30408
-
Expression Region
M1-C202
-
Protein Length
Full Length
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
TM4SF1, a member of the tetraspanin family, is known to play a crucial role in various cellular processes, including cell proliferation, differentiation, and migration. Recent studies have highlighted its potential involvement in cancer progression and immune modulation, making it an attractive target for therapeutic strategies. The use of virus-like particles (VLPs) as a platform for vaccine development and protein delivery has gained significant attention due to their natural ability to elicit robust immune responses. The recombinant expression of TM4SF1 in VLPs presents an innovative approach to harnessing its biological functions while enhancing the immunogenicity of the protein. This strategy not only facilitates the investigation of TM4SF1's role in pathophysiology but also offers a promising avenue for vaccine design against tumors or infectious diseases. By presenting TM4SF1 in a VLP format, researchers aim to improve its stability, facilitate targeted delivery, and evoke a stronger immune response, thereby advancing therapeutic options. Continued research in this domain could pave the way for novel treatments that exploit the unique properties of TM4SF1 and VLPs.
